AUTHORS
Rami Komrokji, MD, Rumana Tokaria, MD2, Najla Al Ali, MS3, Joseph Jabbour4, Rory Shallis, MD5, Zhuoer Xie, MD,MS6, Onyee Chan, MD7, Samuel Benjamin Reynolds, MD8, Andrew T Kuykendall, MD9, Seongseok Yun, MD, PhD10, Kendra L. Sweet, MD, MS11, Alison Walker, MD12, Jeffrey Lancet, MD13, Eric Padron, MD14, David Sallman, MD15
AFFILIATIONS
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
15 Moffitt Cancer Center, Tampa, Florida, United States
ABSTRACT
Introduction
Luspatercept was approved in lower risk MDS(LRMDS) SF3B1 mutant (MT) patients (pts) after erythroid stimulating agents (ESA) failure based on MEDALIST trial and as 1st line therapy in all LRMDS pts based on COMMANDS clinical trial which demonstrated higher response rates and more durable response compared to ESA. However, the benefit of luspatercept in the COMMANDS study was more observed among SF3B1 MT pts. National guidelines and experts recommend using luspatercept as first line therapy in MDS SF3B1 but there remains controversy if luspatercept should be considered standard 1st line therapy among SF3B1 wild type (WT) pts given equivalent response rates compared to ESA. This is more complicated by scarce data on activity of luspatercept post ESA failure in SF3B1 WT and lack of data on activity of ESA after luspatercept failure.
Methods:
We examined all patients treated with luspatercept at our institution as first line or second line therapy after ESA failure for LRMDS anemia. The primary objective was assessing luspatercept response rates based on SF3B1 status, ESA treatment and response, serum erythropoietin level (epo). The response rates are reported according to IWG 2006 hematological improvement (HI-E) criteria. Descriptive statistics were used for baseline characteristics and chi-square or Fishers exact test were used to compare response rates between different groups.
Results
We identified 172 LRMDS pts who received luspatercept as 1st line therapy or after ESA failure. Median age was 70.6 years, 40% females, 67% SF3B1 MT, median IPSS-R score 2, median blasts 2%, median Hgb 9 g/dl, 31.4% RBC- transfusion dependent (RBC-TD), and 74.3% had epo < 200.
The response rates (HI-E) were 58.8% for SF3B1 MT ESA naïve, 35.3% SF3B1 WT ESA naïve, 42.3% for SF3B1 MT after ESA failure and 17.9% for SF3B1 WT after ESA failure. Among patients with prior ESA treatment the SF3B1 MT group had significantly higher odds of response compared to SF3B1 WT, 3.35 (p=0.009), the analogous comparison among ESA naïve pts between SF3B1 MT and WT also demonstrated higher response rate among SF3B1 MT but was not statistically significant given small sample size (17 each group).
Baseline epo levels were available for 113 pts, among SF3B1 MT ESA naïve pts (n=13), response rates were 83.3% with epo < 200 and 42.9% with epo ≥ 200 (p=0.27). For SF3B1 WT ESA naïve (n=11) response rates were 100% with epo < 200 and no response with epo ≥ 200 (p=0.002). There was a trend for higher response rate among non-RBC-TD ESA naïve pts, 70% vs 43% in SF3B1 MT cohort, and 43% vs 30% in SF3B1 WT.
Among SF3B1 MT pts, prior ESA response was associated with a substantially higher luspatercept response rate: 64.3% (18/28) vs 33.3% (23/69) in ESA non-responders. The odds of luspatercept response were 3.60 in prior-ESA responders (p = 0.007). Among SF3B1 WT patients, prior ESA response was not associated with improved luspatercept response: 14.3% (2/14) vs 20.0% (5/25) in ESA non-responders.
Finally, we compared luspatercept and ESA response rates as first line therapy. Luspatercept treated pts were younger, had higher epo level and more likely RBC-TD. Among SF3B1 MT, 17 pts received luspatercept and 97 received ESA as 1st line. The response rate was 52.9% for luspatercept vs 28.9% for ESA, the odds ratio was 2.77 (p=0.089). The adjusted odds ratio was 3.85 - 95% CI 1.21-12.22, p = 0.022. Among SF3B1 WT, 17 pts received luspatercept and 39 received ESA as 1st line. The response rate was 35.3% for luspatercept vs 35.9% for ESA, the odds ratio was 0.97, p=1.0. The adjusted odds ratio was 1.19 - 95% CI 0.30-4.75, p = 0.801.
Conclusions
SF3B1 MT, prior ESA treatment, ESA response, serum epo, and RBC-TD are predictors of response to luspatercept. Among SF3B1 MT MDS pts, luspatercept yields high response rates for both ESA naïve and treated pts. Among SF3B1 WT ESA naïve MDS pts, luspatercept responses are equivalent to ESA and the likelihood of response post ESA treatment is low. Luspatercept combinations or novel alternative therapies should be further explored in SF3B1 WT LR-MDS. The principle of treatment totality and sequencing of therapies to drive maximum benefit of all available options should be thoroughly studied.
DISCLOSURES
Rami Komrokji, MD: Abbvie - Honoraria; syndax - Honoraria; Takeda - Honoraria; Stemline - Honoraria; DSI - Honoraria; BMS - Honoraria; GSK - Honoraria; RIGEL - Honoraria; Sobi - Honoraria; Kura - Honoraria; Servier - Honoraria; Novartis - Honoraria; Sumitomo - Honoraria; GERON - Honoraria; PharmaEssentia - Honoraria; BMS - Research Funding; Takeda - Consultancy (Includes expert testimony); RIGEL - Consultancy (Includes expert testimony); syndax - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); DSI - Consultancy (Includes expert testimony); GERON - Consultancy (Includes expert testimony); Kura - Consultancy (Includes expert testimony); Stemline - Consultancy (Includes expert testimony); Sumitomo - Consultancy (Includes expert testimony)